



Rated AA+ by ICRA

Ref. No. CS/BSE/2024-25/ February/04

12th February 2025

To
BSE Limited
Listing Department
Wholesale Debt Market,
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai - 400 001

Dear Sir/Madam,

Ref: Intimation under Regulation 52(8) read with Part B of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Newspaper publication pertaining to financial results for the period ending December 31, 2024

In continuation of our letter dated 10th February 2025 and pursuant to Regulation 52(8) read with Part B of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of newspaper publication pertaining to financial results for the period ending December 31, 2024. The publication was made in Financials Express, English newspaper on February 12, 2025.

Request you to kindly take the above on record.

Thanking you,

Yours sincerely,

For Universal Sompo General Insurance Co. Ltd.

Aarti Kamath
Company Secretary & Compliance Officer
Membership No: F 6703

Place: Mumbai

FINANCIAL EXPRESS



SUNSHIELD CHEMICALS LIMITED

Corporate Identity Number: L99999MH1986PLC041612 Regd. Office: 1501-A. Universal Majestic, P.L. Lokhande Marg. Behind RBK International School, Chembur-West, Mumbai - 400 043 Phone No. 25550126 | Website: www.sunshieldchemicals.com E Mail: investorservices@sunshleldchemicals.com

Extract of unaudited financial results for the quarter and nine months ended December 31, 2024

Sr.		Quarter ended (Unaudited)			Nine Months ended (Unaudited)		Year ended (Audited)
No.		Dec 31, 2024	Sept 30, 2024	Dec 31, 2023	Dec 31, 2024	Dec 31, 2023	Mar 31, 2024
1	Total income from operations	8,515	9,429	6,557	25,770	19,898	28,486
2	Net Profit for the period / year before tax	237	430	729	1,046	1,817	2,674
3	Net Profit for the period / year after tax	163	319	513	883	1,285	1,884
4	Total Comprehensive Income for the period / year	155	311	516	859	1,295	1,853
5	Paid up equity share capital (face value of Rs.10/- each)	735	735	735	735	735	735
6	Other Equity						7,484
7	Basic & Diluted Earnings per Share (of Rs.10/- each) (not annualised for the quarter)	2.22	4.34	6.97	12.01	17.48	25.62

The aforesaid financial results of Sunshield Chemical Limited (the "Company") were reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at its meeting held on February 11, 2025. The same have been audited by the Statutory Auditors who have issued an unmodified opinion on the aforesaid results.

The above is an extract of the detailed format of quarterly/ year ended Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the guarterly. year ended Financial Results are available on the Stock Exchange website (www.bseindia.com) and also on the Company's

website www.sunshieldchemicals.com

Place: Rasal

Date: February 11, 2025

SUNSHIELD CHEMICALS LIMITED Jeet Malhotra Managing Director & CEO DIN: 07208234

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.



SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

For and on behalf of the Board of Directors

Regd. Office: Plot No. 5&6/1, Savli GIDC Estate, Manjusar 391775, District: Vadodara, Gujarat, India Corporate Office: 17-B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (E), Mumbai 400 093. Tel: (91-22) 6645 5685 CIN: L73100GJ2006PLC047837 Website: www.sparc.life Email: secretarial@sparcmail.com

Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2024

The Unaudited Financial Results of Sun Pharma Advanced Research Company Limited ("SPARC") for the quarter and nine months ended December 31, 2024 ("Q3 FY 25 Results") have been filed with the Stock Exchanges as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Q3 FY 25 Results are available on Company's website, www.sparc.life, and also on the websites of the Stock Exchanges, i.e., www.bseindia.com and www.nseindia.com

For and on behalf of the Board

Dilip S. Shanghvi

Chairman

Mumbai, February 10, 2025

Scan the Ouick Response (QR) code to access the Q3 FY 25 Result.




Shivalik Rasayan Limited

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

CIN: L24237UR1979PLC005041

E-mail: cs@shivalikrasayan.com, www.shivalikrasayan.com



Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on February 11, 2025, approved the unaudited financial results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2024.

The financial results along with Limited Review Report have been posted on the website of the Company at www.shivalikrasayan.com and can be accessed by scanning the QR code given below:

Place: New Delhi Date: 11.02.2025



For and on behalf of Board of Directors of Shivalik Rasayan Limited

> Rahul Bishnoi Director

DIN: 00317960





Sd/-

Nippon Life India Asset Management Limited

(CIN - L65910MH1995PLC220793)

Registered Office: 4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W), Mumbai - 400 013. Tel No. +91 022 6808 7000

Fax No. +91 022 6808 7097 • mf.nipponindiaim.com

NOTICE NO. 81

Record Date February 14 2025#

Notice is hereby given that the Trustee of Nippon India Mutual Fund ("NIMF") has approved the following Distribution on the face value of Rs. 10/- per unit under Income Distribution Cum Capital Withdrawal (IDCW) option of the undernoted schemes of NIMF, with February 14, 2025 as the record date:

Name of the Scheme(s)	Amount of Distribution (₹ per unit)*	NAV as on February 10 2025 (₹ per unit)	
Nippon India Balanced Advantage Fund – IDCW Option	0.2000	32.5049	
Nippon India Balanced Advantage Fund - Direct Plan - IDCW Option	0.2000	44.8075	

*Income distribution will be done, net of tax deducted at source, as applicable. #or the immediately following Business Day if that day is a non-business day

Pursuant to payment of dividend/IDCW, the NAV of the Schemes will fall to the extent of payout, and statutory levy, if any. The IDCW payout will be to the extent of above mentioned Distribution amount per unit or to the extent of available distributable surplus, as on the Record Date mentioned above, whichever is lower.

For units in demat form: IDCW will be paid to those Unitholders/Beneficial Owners whose names appear in the statement of beneficial owners maintained by the Depositories under the IDCW Plan/Option of the Schemes as on record date.

All unit holders under the IDCW Plan/Option of the above mentioned schemes, whose names appear on the register of unit holders on the aforesaid record date, will be entitled to receive the IDCW.

> For Nippon Life India Asset Management Limited (Asset Management Company for Nippon India Mutual Fund)

Mumbai

February 11, 2025

Authorised Signatory

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

SMARTLINK HOLDINGS LIMITED

CIN: L67100GA1993PLC001341

Registered office: Plot No. L-7, Verna Industrial Estate, Verna, Goa - 403 722; Website: www.smartlinkholdings.com

EXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

(₹ In Lakhs except earnings per share)

Particulars	3 months ended 31.12.2024 (Unaudited)	3 months ended 30.09.2024 (Unaudited)	3 months ended 31.12.2023 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2023 (Unaudited)	Year ended 31.03.2024 (Audited)
Total income from operations (net)	5,641.50	5,868.83	4,042.41	15,793.41	13,093.65	20,994.41
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	181.44	130.92	(154.90)	294.74	(179.43)	869.85
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	181.44	130.92	(154.90)	294.74	(179.43)	869.85
Net Profit / (Loss) after taxes, after extraordinary items	254.33	67.04	(121.45)	276.95	(162.36)	705.95
Total Comprehensive income for the period	251.74	60.69	(124.95)	261.65	(172.89)	677.31
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	18,828.11
Earnings per share (before extraordinary items) (of ₹ 2/- each)	53505541		100		555540	
Basic and Diluted	2.55	0.68	(1.22)	2.78	(1.63)	7.08
Earnings per share (after extraordinary items) (of ₹ 2/- each)					77. 5	
Basic and Diluted	2.55	0.68	(1.22)	2.78	(1.63)	7.08

Particulars	3 months ended 31.12.2024 (Unaudited)	Delay Colon Street Street Street		ended 31.12.2024		Year ended 31.03.2024^ (Audited)
Income from Operations	2,961.22	2,674.52	1,701.49	6,751.39	5,205.51	8,845.45
Profit / (Loss) Before Tax	42.88	32.92	59.28	22.90	220.91	730.51
Profit / (Loss) After Tax	150.24	0.82	33.80	79.58	135.75	615.87
Total Comprehensive income for the period	150.46	(2.73)	32.45	72.70	131.41	598.99

Place: Verna, Goa

Date: 10th February, 2025

The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 10, 2025. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.

"Pursuant to the sanction of the Scheme of Amalgamation ('Scheme') between Smartlink Holdings Limited ('Company') and Synegra EMS Limited, a wholly owned subsidiary ('Synegra') of the Company, by the Hon'ble National Company Law Tribunal ('NCLT') vide its order dated January 09, 2025, Synegra has been amalgamated with the Company. Accordingly difference between the value of net assets and reserves and surplus of Synegra has been adjusted against the capital reserves account of the Company, in accordance with the 'Scheme'.

filing the certified copy of the order of NCLT with the Jurisdictional Registrar of Companies. Post the Scheme becoming effective, the Company has ceased to be a Non-Banking Financial Company. The 'Scheme' has been given effect in the financial statements of the Company from the appointed date. Considering that the Scheme of Amalgamation is a common control transaction, in compliance with the requirement of Appendix C

of Ind AS 103 on Business Combinations, the pooling of interest method has been applied and all comparative figures

While the appointed date of the Scheme is April 01, 2024, the Scheme is effective January 31, 2025 i.e. on the day of

presented in these results have been restated to give accounting impact of the Scheme. On account of the Scheme of Amalgamation referred to in Note (b) above, the Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/IT Products.

The above is an extract of the detailed format of Quarterly Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites at https://www.nseindia.com/ and https://www.bseindia.com/ and on the Company's website at https://www.smartlinkholdings.com/investor-relations/ .The same can also be accessed by scanning the QR code provided below.

For and on behalf of the Board

K. R. Naik **Executive Chairman** DIN: 00002013



Universal Sompo General Insurance Co. Ltd.

IRDAI Registration No.134 and Date of Registration with the IRDAI November 16, 2007 | CIN No. U66010MH2007PLC166770 Registered & Corporate Office: 8th Floor and 9th Floor (South Side), Commerz, International Business park, Oberoi Garden City,

Off Western Express Highway, Goregaon East, Mumbai- 400063 • Website: www.universalsompo.com.

Unaudited Financial Results for the Quarter ended December 31, 2024

[Regulation 52(8), read with regulation 52(4) of the Listing Regulations]

(₹ in Lakhs)

		1	AV 15 15	(₹ in Lakhs)	
C- N-		Quarter	Year Ended		
Sr. No	Particulars	December 31, 2024	December 31,2023	March 31, 2024	
		Unaudited	Unaudited	Audited	
1	Premium Income (Gross) (Refer note c)	132,816	118,685	463,789	
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	7,543	7,802	25,404	
3	Net Profit/ (Loss) for the period before tax (after Exceptional and/ or Extraordinary items)	7,543	7,802	25,404	
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	6,031	4,824	18,165	
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	NA	NA	NA	
6	Equity Share Capital	36,818	36,818	36,818	
7	Reserves (excluding Revaluation Reserve)	108,409	90,428	90,537	
8	Securities Premium Account	16,762	16,762	16,762	
9	Net worth	161,989	144,008	144,117	
10	Paid up Debt Capital/ Outstanding Debt	NA	NA	NA	
11	Outstanding Redeemable Preference Shares	NA	NA	NA	
12	Debt Equity Ratio (No. of times)	0.09	233.00	- 1	
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)	0.8302.83			
	Basic:	1.64	1.31	4.93	
	Diluted:	1.64	1.31	4.93	
14	Capital Redemption Reserve	NA	NA	NA	
15	Debenture Redemption Reserve	1000	2000		
16	Debt Service Coverage Ratio (No. of times)	21.22	2	92	
17	Interest Service Coverage Ratio (No. of times)	21.22	8	-	

Notes:

This format is modified to reflect the terminology used in the Insurance Act/IRDAI Regulations.

The above is an extract of the detailed format of Quarterly and Nine months ended Financial Results filed with the Stock Exchanges under Regulation 52(8), read with Regulation 52(4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine months ended Financial Results are available on the websites of the Stock Exchange and the Company's website 'https://www.universalsompo.com'.

Premium income is Gross Written Premium, gross of reinsurance and net of GST.

Line Item No. 5 would be disclosed when Ind AS become applicable to Insurance companies.

Net Profit/(Loss) before tax, for the period is Profit/(Loss) before tax as appearing in Profit and Loss Account (Shareholders'

Reserves are excluding Revaluation reserve and fair value change account.

The Company has issued and allotted 15,000 Unsecured, rated, listed, redeemable, fully paid up, non-cumulative, subordinated, Non-Convertible Debentures (NCDs) in the nature of 'Subordinated Debt' in accordance with IRDAI (Registration, Capital Structure, Transfer of Shares and Amalgamation of Insurers) Regulations, 2024, the Companies Act, 2013 and the SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021, as amended, of face value of ₹1 lakh (each at par) aggregating to ₹15,000 lakhs through private placement on July 25, 2024.

Debt-equity ratio is calculated as Total borrowings divided by Net worth.

Debt service coverage ratio is calculated as Profit before interest and tax divided by interest expense together with principal repayments of long term debt during the period.

Interest service coverage ratio is calculated as Profit before interest and tax divided by interest expense.

For and on behalf of the Board of Directors Sharad Mathur Managing Director & CEO

financialexp.epapr.in

Date: February 10, 2025

Place: Mumbai

DIN No. 08754740